Ubs Group Ag Applied Therapeutics Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 283,685 shares of APLT stock, worth $241,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

283,685

Previous 172,063 64.87%

Holding current value

$241,132

Previous $803,000 200.25%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.35 - $8.5 $485,555 - $948,787	111,622 Added 64.87%	283,685 $2.41 Million
Q2 2024 Aug 13, 2024	BUY	$4.04 - $6.37 $77,984 - $122,960	19,303 Added 12.64%	172,063 $803,000
Q1 2024 May 13, 2024	BUY	$2.25 - $7.4 $73,244 - $240,892	32,553 Added 27.08%	152,760 $1.04 Million
Q4 2023 Feb 09, 2024	BUY	$1.84 - $3.35 $21,759 - $39,617	11,826 Added 10.91%	120,207 $402,000
Q3 2023 Nov 09, 2023	BUY	$1.26 - $2.77 $2,189 - $4,814	1,738 Added 1.63%	108,381 $269,000
Q2 2023 Aug 11, 2023	BUY	$0.77 - $1.8 $25,365 - $59,295	32,942 Added 44.7%	106,643 $136,000
Q1 2023 May 12, 2023	BUY	$0.75 - $1.21 $46,749 - $75,422	62,333 Added 548.32%	73,701 $59,000
Q4 2022 Feb 08, 2023	SELL	$0.54 - $1.12 $8,521 - $17,674	-15,781 Reduced 58.13%	11,368 $8,000
Q3 2022 Nov 10, 2022	BUY	$0.86 - $1.55 $1,105 - $1,993	1,286 Added 4.97%	27,149 $26,000
Q2 2022 Aug 10, 2022	BUY	$0.76 - $2.64 $2,926 - $10,164	3,850 Added 17.49%	25,863 $24,000
Q1 2022 May 16, 2022	SELL	$1.48 - $6.22 $77,563 - $325,977	-52,408 Reduced 70.42%	22,013 $47,000
Q4 2021 Feb 14, 2022	BUY	$8.77 - $18.29 $466,660 - $973,229	53,211 Added 250.88%	74,421 $666,000
Q3 2021 Nov 15, 2021	SELL	$13.54 - $22.06 $14,555 - $23,714	-1,075 Reduced 4.82%	21,210 $352,000
Q2 2021 Aug 13, 2021	SELL	$14.05 - $25.04 $61,187 - $109,049	-4,355 Reduced 16.35%	22,285 $463,000
Q1 2021 May 12, 2021	BUY	$16.57 - $28.65 $39,088 - $67,585	2,359 Added 9.72%	26,640 $500,000
Q4 2020 Feb 11, 2021	SELL	$15.44 - $24.23 $1.21 Million - $1.9 Million	-78,409 Reduced 76.36%	24,281 $535,000
Q3 2020 Nov 12, 2020	BUY	$19.43 - $35.36 $397,343 - $723,112	20,450 Added 24.87%	102,690 $2.13 Million
Q2 2020 Jul 31, 2020	BUY	$29.41 - $51.23 $2.27 Million - $3.96 Million	77,205 Added 1533.37%	82,240 $2.97 Million
Q1 2020 May 01, 2020	SELL	$19.54 - $55.47 $101,412 - $287,889	-5,190 Reduced 50.76%	5,035 $164,000
Q4 2019 Feb 14, 2020	BUY	$10.16 - $28.14 $65,857 - $182,403	6,482 Added 173.18%	10,225 $279,000
Q3 2019 Nov 14, 2019	BUY	$8.08 - $10.99 $12,919 - $17,573	1,599 Added 74.58%	3,743 $41,000
Q2 2019 Aug 14, 2019	BUY	$8.1 - $10.05 $17,366 - $21,547	2,144 New	2,144 $18,000

Others Institutions Holding APLT

# of Institutions

140

Shares Held

112M

Call Options Held

1.68M

Put Options Held

1.91M

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $40.8M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account